Ha Yan Kang
Dankook University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ha Yan Kang.
Liver International | 2013
Do Young Kim; In Hee Kim; Sook Hyang Jeong; Yong Kyun Cho; Joon Lee; Young Joo Jin; Don Lee; Dong Jin Suh; Kwang Hyub Han; Neung Hwa Park; Ha Yan Kang; Young Kul Jung; Young Seok Kim; Kyung Ah Kim; Youn Jae Lee; Byung Seok Lee; Hyung Joon Yim; Heon Ju Lee; Soon Koo Baik; Won Young Tak; Sun Jae Lee; Woo Jin Chung; Sung Kyu Choi; Eun Young Cho; Jeong Heo; Dong Joon Kim; Byung Cheol Song; Man Woo Kim; Jun Lee; Hee Bok Chae
The aim of this study was to reveal nationwide seroprevalence of HCV infection in South Korea by a large‐scale survey.
The Korean Journal of Hepatology | 2012
Sang Seok Lee; Hyun Sung Shin; Hyung Joon Kim; Su Jin Lee; Hyun Suk Lee; Kyung Hee Hyun; Yong Hyun Kim; Byoung Woon Kwon; Jin Hyung Han; Hoon Choi; Bae Hwan Kim; Joon Hyuk Lee; Ha Yan Kang; Hyun Deok Shin; Il Han Song
Background/Aims Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. Methods In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. Results The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. Conclusions This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.
Journal of Korean Medical Science | 2009
Ha Yan Kang; Ran Noh; So Mi Kim; Hyun Deok Shin; Se Young Yun; Il Han Song
Phlebosclerotic colitis is a rare form of ischemic colitis characterized by the thickening of the wall of the affected colon due to fibrous degeneration of submucosal layer of colon and fibrotic obstruction of the colono-mesenteric vein, resulting in the disturbance of venous return from the colon. The pathogenic mechanism of this entity remains unknown but chronic liver disease with portal hypertension is maybe thought to be one of the speculated mechanisms. Here we first report the case of surgically confirmed phlebosclerotic colitis, that was in the early stage but showed the aggressive nature, in a 61-yr-old cirrhotic patients with portal hypertension in Korea.
World Journal of Gastroenterology | 2012
Suk Bae Kim; Il Han Song; Young-Min Kim; Ran Noh; Ha Yan Kang; Hyang Ie Lee; Hyeon Yoong Yang; An Na Kim; Hee Bok Chae; Sae Hwan Lee; Hong Soo Kim; Tae Hee Lee; Young Woo Kang; Eaum Seok Lee; Seok Hyun Kim; Byung Seok Lee; Heon Young Lee
AIM To evaluate the treatment outcomes of clevudine compared with entecavir in antiviral-naive patients with chronic hepatitis B (CHB). METHODS We retrospectively analyzed the clinical data of CHB patients treated with clevudine 30 mg/d and compared their clinical outcomes with patients treated with entecavir 0.5 mg/d. The biochemical response, as assessed by serum alanine aminotransferase (ALT) activity, virologic response, as assessed by serum hepatitis B virus DNA (HBV DNA) titer, serologic response, as assessed by hepatitis B e antigen (HBeAg) status, and virologic breakthrough with genotypic mutations were assessed. RESULTS Two-hundred and fifty-four patients [clevudine (n = 118) vs entecavir (n = 136)] were enrolled. In clevudine-treated patients, the cumulative rates of serum ALT normalization were 83.9% at week 48 and 91.5% at week 96 (80.9% and 91.2% in the entecavir group, respectively), the mean titer changes in serum HBV DNA were -6.03 and -6.55 log(10) copies/mL (-6.35 and -6.86 log(10) copies/mL, respectively, in the entecavir group), and the cumulative non-detection rates of serum HBV DNA were 72.6% and 83.1% (74.4% and 83.8%, respectively, in the entecavir group). These results were similar to those of entecavir-treated patients. The cumulative rates of HBeAg seroconversion were 21.8% at week 48 and 25.0% at week 96 in patients treated with clevudine, which was similar to patients treated with entecavir (22.8% and 27.7%, respectively). The virologic breakthrough in the clevudine group occurred in 9 (7.6%) patients at weeks 48 and 15 (12.7%) patients at week 96, which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M. There was no virologic breakthrough in the entecavir group. CONCLUSION In antiviral-naive CHB patients, long-term treatment outcomes of clevudine were not inferior to those of entecavir, except for virologic breakthrough.
The Korean Journal of Hepatology | 2011
Ha Yan Kang; Won Kyung Lee; Yong Hyun Kim; Byung Woon Kwon; Myung Soo Kang; Suk Bae Kim; Il Han Song
Duodenal varices result from retroperitoneal portosystemic shunts that usually come from the pancreaticoduodenal vein and drain into the inferior vena cava. Because they are a rare but fatal cause of gastrointestinal bleeding, a prompt hemostatic intervention is mandatory. A 62-year-old man who had a history of excessive alcohol consumption presented with massive hematemesis and melena. Emergent endoscopy revealed ruptured varices with an adhering whitish fibrin clot on the postbulbar portion of the duodenum. Abdominal computed tomography demonstrated a cirrhotic liver with venous collaterals around the duodenum and extravasated contrast in the second and third portions. The collaterals originated from the main portal vein and drained via the right renal vein into the inferior vena cava. Endoscopic injection sclerotherapy with cyanoacrylate was successful in achieving hemostasis, and resulted in the near eradication of duodenal varices at a 6-month follow-up.
Journal of Medical Case Reports | 2014
Ha Yan Kang; Sung Hoon Moon; Il Han Song
IntroductionSorafenib, a multikinase inhibitor as a standard of care for advanced hepatocellular carcinoma, may lead endothelial cells to an unstable state by blocking the signaling pathway of vascular endothelial growth factor receptor, which may result in the disruption of the architecture and integrity of the microvasculature, and eventually increase the risk of hemorrhage. Hemobilia is a relatively uncommon condition as a consequence of hepatocellular carcinoma and its risk factors remain uncertain.Case presentationHere we report a unique case of hemobilia occurring in a 55-year-old Korean man with hepatitis B virus-related hepatocellular carcinoma on Barcelona Clinic Liver Cancer advanced stage after seven days of treatment with sorafenib. He had received prior radiation therapy. Endoscopy revealed bleeding from the major duodenal papilla and endoscopic retrograde cholangiography revealed an amorphous filling defect throughout the common bile duct. Blood clots were removed by balloon sweeping and a nasobiliary drainage tube was placed. No further bleeding has been detected as of eight months after discontinuation of sorafenib.ConclusionSorafenib may increase the risk of biliary bleeding in hepatocellular carcinoma patients who were primed with irradiation, by blocking the signaling pathway of the vascular endothelial growth factor receptor. Therefore, sorafenib should be used with caution in patients with advanced hepatocellular carcinoma, especially when combined with radiation therapy.
The Korean Journal of Gastroenterology | 2017
Chang Seok Bang; Ha Yan Kang; Gyu Ho Choi; Suk Bae Kim; Wonae Lee; Il Han Song
Background/Aims The invasiveness of a liver biopsy and its inconsistent results have prompted efforts to develop noninvasive tools to evaluate the severity of chronic hepatitis. This study was intended to assess the performance of serum biomarkers for predicting liver fibrosis in patients with chronic viral hepatitis. Methods A total of 302 patients with chronic hepatitis B or C, who had undergone liver biopsy, were retrospectively enrolled. We investigated the diagnostic accuracy of several clinical factors for predicting advanced fibrosis (F≥3). Results The study population included 227 patients with chronic hepatitis B, 73 patients with chronic hepatitis C, and 2 patients with co-infection (hepatitis B and C). Histological cirrhosis was identified in 16.2% of the study population. The grade of porto-periportal activity was more correlated with the stage of chronic hepatitis compared with that of lobular activity (r=0.640 vs. r=0.171). Fibrosis stage was correlated with platelet count (r=-0.520), aspartate aminotransferase to platelet ratio index (APRI) (r=0.390), prothrombin time (r=0.376), and albumin (r=-0.357). For the diagnosis of advanced fibrosis, platelet count and APRI were the most predictive variables (AUROC=0.752, and 0.713, respectively). Conclusions In a hepatitis B endemic region, platelet count and APRI could be considered as reliable non-invasive markers for predicting fibrosis of chronic viral hepatitis. However, it is necessary to validate the diagnostic accuracy of these markers in another population.
Clinics and Research in Hepatology and Gastroenterology | 2012
Ha Yan Kang; Hyun Deok Shin; Suk Bae Kim; Il Han Song
BACKGROUND There is no worldwide consensus on clinical application of staging systems that have been proposed for hepatocellular carcinoma (HCC). This study evaluated the predictors of survival and compared the prognosis predictability according to staging systems of HCC. PATIENTS AND METHODS We analyzed the medical records of 142 patients who were consecutively diagnosed as HCC in hepatitis B virus (HBV)-endemic area. To analyze the survival predictors and probability of staging systems, Kaplan-Meier method and Cox proportional hazard model were used. And to compare the discriminatory ability and predictive power of staging systems for prognosis and survival, likelyhood ratio χ(2) test and Akaike information criterion were applied. RESULTS Overall median survival of HCC patients was 24 months and 1-, 2-, and 3-year survival rate was 61.3, 49.4, and 45.7%, respectively. Child-Pugh classification (P=0.038) and portal vein thrombosis (PVT) (P=0.022) were ascertained as independent predictors of survival. Although all the staging systems showed a progressive decrease in survival as the tumor stage progressively advanced, the Japan Integrated Staging (JIS) and Chinese University Prognostic Index (CUPI) showed the highest homogeneity (small differences in survival among patients in the same stages), and the best monotonicity of gradient (the survival of patients in earlier stages is longer than the survival of patients in more advanced stages within the same system), respectively. CONCLUSION In HBV-endemic area, Child-Pugh classification and PVT were independent predictors for survival, and JIS and CUPI were the most powerful staging systems to predict the prognosis of HCC.
Gastroenterology | 2013
Yong Hyun Kim; Byoung Woon Kwon; Ran Noh; Ha Yan Kang; Suk Bae Kim; Il Song
A S L D A b st ra ct s who had recently used antibiotics. The high prevalence suggests there may be an important role of chronic bacterial infection in this population, and how this may lead to spontaneous bacterial peritonitis. Whether this is due to altered gut immunity, altered gastrointestinal transit or autonomic dysfunction secondary to a metabolic disorder merits further systematic evaluation. Duodenal aspiration/culture, appears to be more sensitive and specific than GBT in detecting SIBO in this population.
Clinics and Research in Hepatology and Gastroenterology | 2012
Hoon Choi; Ha Yan Kang; Il Han Song
d m s t c o A 31-year-old man with alcoholic cirrhosis presented to emergency department with a 3-day history of severe retrosternal pain and dyspnea following violent retching. He was hemodynamically stable except low-grade fever. Chest CT (Fig. 1A and B) showed a concentric low-attenuated wall thickening with several intramural defects on entire esophagus and proximal stomach (arrows), diffuse haziness of mediastinal fat, bilateral pleural effusion and consolidation in the left lower lung field. Endoscopy revealed a circumferential, diffuse subepithelial edema with bluish